Source:http://linkedlifedata.com/resource/pubmed/id/20926750
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2011-2-25
|
| pubmed:abstractText |
The purpose of this open-label, parallel-group study was to investigate the effect of severe renal impairment on the pharmacokinetics (PK), tolerability, and safety of clazosentan, an intravenous endothelin receptor antagonist. Clazosentan was administered as a continuous intravenous infusion of 1 mg/h for a period of 6 hours in 9 subjects with severe renal impairment (group A) and 8 healthy subjects (group B) (creatinine clearance <30 mL/min and >80 mL/min, respectively). The subjects in both groups were well matched for sex, body mass index, and age (±10 years). The PK parameters of clazosentan were calculated by both model-independent and model-dependent methods. The differences in the PK parameters between the subjects with severe renal impairment and healthy subjects were minor. The geometric means for area under the curve (AUC) during the infusion, AUC(0-t), (AUC from zero to time t of the last measured concentration above the limit of quantification) AUC(0-?) (AUC from zero to infinity), and concentration at steady state were 7%, 8%, 8%, and 8%, respectively, higher in group A than in group B. The results obtained after 2-compartmental modeling were in agreement with those obtained after noncompartmental analysis. Administration of clazosentan was well tolerated in both groups. The data suggest that there is no need for dose adjustment of clazosentan in patients with renal impairment.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Dioxanes,
http://linkedlifedata.com/resource/pubmed/chemical/Pyridines,
http://linkedlifedata.com/resource/pubmed/chemical/Pyrimidines,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Endothelin A,
http://linkedlifedata.com/resource/pubmed/chemical/Sulfonamides,
http://linkedlifedata.com/resource/pubmed/chemical/Tetrazoles,
http://linkedlifedata.com/resource/pubmed/chemical/clazosentan
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
1552-4604
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
51
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
413-21
|
| pubmed:meshHeading |
pubmed-meshheading:20926750-Adult,
pubmed-meshheading:20926750-Dioxanes,
pubmed-meshheading:20926750-Female,
pubmed-meshheading:20926750-Half-Life,
pubmed-meshheading:20926750-Humans,
pubmed-meshheading:20926750-Infusions, Intravenous,
pubmed-meshheading:20926750-Kidney Failure, Chronic,
pubmed-meshheading:20926750-Male,
pubmed-meshheading:20926750-Metabolic Clearance Rate,
pubmed-meshheading:20926750-Middle Aged,
pubmed-meshheading:20926750-Models, Biological,
pubmed-meshheading:20926750-Pyridines,
pubmed-meshheading:20926750-Pyrimidines,
pubmed-meshheading:20926750-Receptor, Endothelin A,
pubmed-meshheading:20926750-Renal Insufficiency,
pubmed-meshheading:20926750-Severity of Illness Index,
pubmed-meshheading:20926750-Subarachnoid Hemorrhage,
pubmed-meshheading:20926750-Sulfonamides,
pubmed-meshheading:20926750-Tetrazoles,
pubmed-meshheading:20926750-Vasospasm, Intracranial
|
| pubmed:year |
2011
|
| pubmed:articleTitle |
Influence of severe renal impairment on the pharmacokinetics of clazosentan.
|
| pubmed:affiliation |
Actelion Pharmaceuticals Ltd, Department of Clinical Pharmacology, Gewerbestrasse 3, 4123 Allschwil, Switzerland. Shirin.bruderer@actelion.com
|
| pubmed:publicationType |
Journal Article,
Controlled Clinical Trial
|